Four Pralatrexate (PDX) Studies Accepted for Presentation at the 50th Annual Meeting of the American Society of Hematology
31 10월 2008 - 5:00AM
Business Wire
Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical
company focused on the development and commercialization of small
molecule therapeutics for the treatment of cancer, today announced
that four abstracts describing results from pralatrexate (PDX)
studies have been accepted for presentation at the 50th Annual
Meeting of the American Society of Hematology (ASH), to be held
December 6 - 9, 2008, in San Francisco, California. The accepted
abstracts describe several clinical and pre-clinical pralatrexate
studies, as follows: �PROPEL: A Multi-center Phase 2 Open-label
Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid
Supplementation in Patients with Relapsed or Refractory Peripheral
T-cell Lymphoma (PTCL).� Owen O'Connor, M.D. Ph.D., Director
Lymphoid Development and Malignancy Program and Chief of the
Lymphoma Service at the Irving Comprehensive Cancer Center at
Columbia University Medical Center, is scheduled to report top line
results from the PROPEL trial in an oral presentation. Dr. O�Connor
is Principal Investigator of the trial. �A Phase 1/2a Open-label
Study of Pralatrexate and Gemcitabine in Patients with Relapsed or
Refractory Lymphoproliferative Malignancies.� Steven Horwitz, M.D.,
Assistant Attending Physician, Lymphoma Service, Memorial
Sloan-Kettering Cancer Center, will present interim data from this
study. Dr. Horwitz is serving as the study chair. �Pralatrexate
(PDX) is Active in Cutaneous T-Cell Lymphoma: Preliminary Results
of a Multi-center Dose-finding Trial.� Dr. Horwitz will present
interim data from the Company�s ongoing Phase 1 trial of
pralatrexate in patients with relapsed or refractory cutaneous
T-cell lymphoma. �Pralatrexate (PDX) Compliments the Activity of
the Proteasome Inhibitor Bortezomib (B) in In Vitro Model of
Lymphoid T-Cell Malignancies.� Dr. O�Connor will present results
from a pre-clinical study of a combination of pralatrexate and
Velcade� (bortezomib). About Allos Therapeutics, Inc. Allos
Therapeutics is a biopharmaceutical company focused on developing
and commercializing innovative small molecule drugs for the
treatment of cancer.�The Company's lead product candidate,
pralatrexate (PDX), is a novel antifolate currently under
evaluation in a pivotal Phase 2 (PROPEL) trial in patients with
relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial
is being conducted under an agreement reached with the U.S. Food
and Drug Administration under its special protocol assessment, or
SPA process. The Company is also investigating pralatrexate in
patients with non-small cell lung cancer, bladder cancer and a
range of lymphoma sub-types.�The Company's other product
candidate�is RH1, a targeted chemotherapeutic agent currently being
evaluated in a Phase 1 trial in patients with advanced solid tumors
or non-Hodgkin�s lymphoma (NHL). The Company currently retains
exclusive worldwide rights to pralatrexate and RH1 for all
indications. For additional information, please visit the Company�s
website at www.allos.com. Safe Harbor Statement The anticipated
presentations may contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentation and others that can be found in the
"Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2007 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company does not undertake any obligation to update any
forward-looking statements contained in the anticipated
presentation as a result of new information, future events or
otherwise. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in the
presentation. No forward-looking statement can be guaranteed and
actual events and results may differ materially from those
projected.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics News Articles